Joshua Schimmer
Stock Analyst at Cantor Fitzgerald
(1.37)
# 3,635
Out of 5,124 analysts
23
Total ratings
56.25%
Success rate
-6.96%
Average return
Main Sectors:
Stocks Rated by Joshua Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Reiterates: Overweight | $50 | $2.19 | +2,183.11% | 4 | Apr 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Reiterates: Overweight | $50 | $78.99 | -36.70% | 2 | Nov 15, 2023 | |
| OTIS Otis Worldwide | Maintains: Equal-Weight | $91 → $92 | $87.35 | +5.32% | 4 | Jul 27, 2023 | |
| RNA Avidity Biosciences | Downgrades: In-Line | $20 | $72.13 | -72.27% | 1 | Mar 31, 2023 | |
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $130 | $141.83 | -8.34% | 1 | Mar 3, 2023 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $80 → $50 | $16.51 | +202.85% | 1 | Feb 28, 2023 | |
| TGTX TG Therapeutics | Maintains: Outperform | $16 → $25 | $29.81 | -16.14% | 3 | Jan 24, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $65 → $75 | $3.51 | +2,036.75% | 1 | Sep 30, 2022 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $90 → $100 | $59.43 | +68.27% | 1 | Mar 1, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | n/a | $771.87 | - | 2 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $98.77 | -13.94% | 3 | May 31, 2018 |
Cabaletta Bio
Apr 5, 2024
Reiterates: Overweight
Price Target: $50
Current: $2.19
Upside: +2,183.11%
Mirum Pharmaceuticals
Nov 15, 2023
Reiterates: Overweight
Price Target: $50
Current: $78.99
Upside: -36.70%
Otis Worldwide
Jul 27, 2023
Maintains: Equal-Weight
Price Target: $91 → $92
Current: $87.35
Upside: +5.32%
Avidity Biosciences
Mar 31, 2023
Downgrades: In-Line
Price Target: $20
Current: $72.13
Upside: -72.27%
Neurocrine Biosciences
Mar 3, 2023
Upgrades: Outperform
Price Target: $130
Current: $141.83
Upside: -8.34%
Denali Therapeutics
Feb 28, 2023
Maintains: Outperform
Price Target: $80 → $50
Current: $16.51
Upside: +202.85%
TG Therapeutics
Jan 24, 2023
Maintains: Outperform
Price Target: $16 → $25
Current: $29.81
Upside: -16.14%
Rocket Pharmaceuticals
Sep 30, 2022
Maintains: Outperform
Price Target: $65 → $75
Current: $3.51
Upside: +2,036.75%
BioMarin Pharmaceutical
Mar 1, 2021
Upgrades: Outperform
Price Target: $90 → $100
Current: $59.43
Upside: +68.27%
Regeneron Pharmaceuticals
Feb 25, 2020
Upgrades: Outperform
Price Target: n/a
Current: $771.87
Upside: -
May 31, 2018
Assumes: Overweight
Price Target: $85
Current: $98.77
Upside: -13.94%